Inocras Announces ASCO 2026 Online Publication: Whole-Genome HRD Phenotyping as a Predictor of PARP Inhibitor Benefit in First-Line Maintenance High-Grade Serous Ovarian Cancer

Key Takeaways

• WGS‑HRD positivity linked to 27.5‑month median PFS vs 12 months
• First‑line maintenance patients showed 44.2‑month PFS when HRD‑positive
• 21.4% of HRD‑positive cases lacked BRCA mutations, expanding eligibility
• WGS‑HRD outperformed scarHRD in predicting PARP inhibitor response

Pulse Analysis

Whole-genome sequencing (WGS) has emerged as a powerful tool for assessing homologous recombination deficiency (HRD), a key driver of sensitivity to PARP inhibitors in ovarian cancer. Traditional BRCA testing and scar‑based assays capture only a subset of HRD‑positive tumors, leaving many patients without optimal therapeutic guidance. Inocras’ CancerVision platform integrates matched tumor‑normal WGS to generate a comprehensive HRD score, promising a more inclusive biomarker that aligns with the move toward genome‑wide precision oncology. This shift reflects industry demand for assays that can predict treatment benefit across diverse molecular backgrounds.

The ASCO‑2026 abstract reports real‑world evidence from 84 high‑grade serous ovarian cancer patients treated at Severance Hospital. WGS‑HRD‑positive cases showed a median progression‑free survival (mPFS) of 27.5 months versus 12.0 months for HRD‑negative, with the gap widening to 44.2 versus 10.0 months when therapy was administered as first‑line maintenance. Notably, 21.4% of responders lacked BRCA mutations, underscoring WGS‑HRD’s ability to uncover hidden benefit. In the second‑line setting, HRD status did not correlate with outcomes, suggesting timing influences predictive power.

These findings position WGS‑based HRD scoring as a potential complement—or even alternative—to existing companion diagnostics, accelerating patient stratification for PARP inhibitor regimens. For Inocras, the data bolster the commercial case for CancerVision, reinforcing its CLIA/CAP‑certified status and expanding its appeal to pharma partners seeking robust genomic endpoints in clinical trials. As prospective validation studies launch, the oncology community will watch whether broader adoption translates into improved survival metrics and cost‑effective care, a pivotal step toward truly personalized cancer treatment.